These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 37458554)
1. [Toxicity of targeted therapies and immunotherapy with checkpointinhibitors in Hodgkin lymphoma]. Michot JM; Lazarovici J Rev Prat; 2023 Jun; 73(6):641-650. PubMed ID: 37458554 [TBL] [Abstract][Full Text] [Related]
2. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039 [TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579 [TBL] [Abstract][Full Text] [Related]
4. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585 [TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL; Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562 [TBL] [Abstract][Full Text] [Related]
6. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition? Othman T; Herrera A; Mei M Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966 [TBL] [Abstract][Full Text] [Related]
7. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma? Goyal SD; Bartlett NL Curr Hematol Malig Rep; 2012 Sep; 7(3):179-85. PubMed ID: 22669711 [TBL] [Abstract][Full Text] [Related]
8. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin. Mei M; Thomas S; Chen R BioDrugs; 2014 Jun; 28(3):245-51. PubMed ID: 24258497 [TBL] [Abstract][Full Text] [Related]
9. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862 [TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. Bradley AM; Devine M; DeRemer D Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511 [TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817 [TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma. Agrusa JE; Egress ER; Lowe EJ Front Immunol; 2023; 14():1203471. PubMed ID: 37275877 [TBL] [Abstract][Full Text] [Related]
13. Novel Therapies in the Treatment of Hodgkin Lymphoma. Andrade-Gonzalez X; Ansell SM Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826 [TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. Forero-Torres A; Fanale M; Advani R; Bartlett NL; Rosenblatt JD; Kennedy DA; Younes A Oncologist; 2012; 17(8):1073-80. PubMed ID: 22855426 [TBL] [Abstract][Full Text] [Related]
15. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma]. Maruyama D Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053 [TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma. Chen R; Chen B Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209 [TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin. van de Donk NW; Dhimolea E MAbs; 2012; 4(4):458-65. PubMed ID: 22684302 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017 [TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022 [TBL] [Abstract][Full Text] [Related]
20. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. Oak E; Bartlett NL Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]